Rchr
J-GLOBAL ID:202101003290649636   Update date: Oct. 07, 2025

matsuo eri

matsuo eri
Research field  (2): Pathobiochemistry ,  Molecular biology
Research theme for competitive and other funds  (5):
  • 2024 - 2027 COVID-19血管病変のメカノトランスダクション制御
  • 2018 - 2021 Establishment of evaluation method for arteriosclerotic lesions by measuring the "hardness" of blood vessels using an atomic force microscope
  • 2012 - 2016 Pharmacological preconditioning of lung with monophosphoryl lipid A: A role of MyD88-independent signaling pathway.
  • 2012 - 2016 Erythropoietin attenuates the sequels of ischaemic spinal cord injury with enhanced recruitment of CD34+ cells in mice
  • 2012 - 2016 Specific inhibition of tenascin-C with Cilostazol attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats
Papers (7):
more...
MISC (4):
Patents (3):
  • 乳酸菌含有食品組成物
  • 口腔乾燥症用組成物
  • プロテアーゼ阻害剤
Lectures and oral presentations  (6):
  • SARS-CoV-2 S1 protein binds to beta-1 integrins to trigger integrin-mediated activation pathway
    (2021)
  • 新規インテグリンリガンドの研究:白血球インテグリンはCOVID-19スパイク蛋白やイリシンに結合する
    (日本集中治療医学会 第5回 東海北陸支部学術集会 2021)
  • 細胞接着基質の硬さがVEGF誘導性の血管内皮細胞の遺伝子発現に及ぼす影響
    (日本血栓止血学会 2021)
  • Phosphorylation enhances recombinant heat shock protein 27 performs as pharmacological preconditioning to protect against lung ischemia reperfusion injury
    (2020)
  • 細胞外環境の硬さによる血管内皮細胞の機能変化の解析(会議録)
    (日本血栓止血学会誌 2020)
more...
Work history (1):
  • 2009/11 - 現在 Mie University Faculty of Medicine
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page